177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR)
Take-home: The phase II LUNAR trial investigated whether adding PSMA-targeted radioligand therapy (¹⁷⁷Lu-PNT2002) before stereotactic body radiotherapy (SBRT) improves outcomes in oligorecurrent hormone-sensitive prostate cancer. Among 92 randomized patients, combination therapy significantly prolonged median progression-free survival from 7.4 to 17.6 months.
About this highlight
177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
Amar U. Kishan, Luca F. Valle, Holly Wilhalme, Carol Felix, Rejah Nabong, Jesus E. Juarez-Casillas, Kevin Flores, T. Martin Ma, Vinicius Ludwig, Mariko Nakayama, Zachary Ells, Magnus Dahlbom, Michael Lauria, Catherine Meyer, Minsong Cao, Joanne B. Weidhaas, Donatello Telesca, Kristen McGreevy, Nicholas G. Nickols, Danielle Karasik, Sophia Parmisano, T. Vincent Basehart, Wayne Brisbane, Leonard Marks, Matthew B. Rettig, Robert E. Reiter, Paul C. Boutros, Martin Allen-Auerbach, Johannes Czernin, Michael L. Steinberg, Jeremie Calais. Journal of Clinical Oncology
- Type
- Publication pick
- Topic
- Genitourinary
